Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre de Recherche Médicale de Lambaréné
• Treatments: Artefenomel; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinine; Artemisinins; Artesunate; Ferroquine; Lumefantrine; Pyronaridine

Criteria

Inclusion Criteria:

• Malaria infection diagnosed by Rapid Diagnostic Tests (RDTs) or thick blood smear

• Urinary schistosomiasis diagnosed by presence of Schistosoma haematobium eggs in the urine before malaria treatment

• Written informed consent

Exclusion Criteria:

• Patients treated with PZQ during the previous 6 weeks

• Known intolerance /allergy to any study drug

• Pregnancy